The consistent upregulation of Trem2, Anxa2, Ttc39a, and Gdf15 across all stages of liver disease—from steatosis and NASH to fibrosis—suggests that these genes play a pivotal role in the progression of NAFLD. This evidence concerns the gene TTC39A and metabolic dysfunction-associated steatotic liver disease.